![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Under the agreement, Reprocell will provide support for Lantern Pharma's Phase 2 trial of LP-300 (tavocept) in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with TKIs.
Lead Product(s): Dimesna,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: LP-300
Highest Development Status: Phase II Product Type: Small molecule
Recipient: Lantern Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2023
Details:
REPROCELL's IBD culture studies have dynamically informed the potential of the HT-003 therapeutic platform, including focusing future development on lead candidate molecules with optimized target responses for ulcerative colitis and Crohn's disease.
Lead Product(s): HT-003
Therapeutic Area: Gastroenterology Product Name: HT-003
Highest Development Status: Preclinical Product Type: Small molecule
Recipient: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 19, 2021
Details:
Fresh explants of ulcerative colitis and Crohn's disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases.
Lead Product(s): HT-003
Therapeutic Area: Gastroenterology Product Name: HT-003
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 11, 2021